

# LITERATURA

1. Adhikari NK, Burns KE, Friedrich JO, et al. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. *BMJ*. 2007;334(7597):779–86.
2. Al-Ani AM. Pulmonary Echinococcosis. *Ann Clin Pathol*. 2016;4(1):1062–4.
3. Almirall J, Serra-Prat M, Bolibar I. Risk factors for community-acquired pneumonia in adults: Recommendations for its prevention. *Community Acquir Infect*. 2015;2(2):32–7.
4. Alvarez-Martínez MJ, Miró JM, Valls ME, et al. Sensitivity and specificity of nested and real-time PCR for the detection of *Pneumocystis jiroveci* in clinical specimens. *Diagn Microbiol Infect Dis*. 2006;56(2):153–60.
5. Amanullah S, Posner DH, Talavera F, et al. Ventilator-Associated Pneumonia Overview of Nosocomial Pneumonias, Medscape. [updated 2015 Dec 31; cited 2017 Mar 18]. Available from: <http://emedicine.medscape.com/article/304836-overview#a1>.
6. American thoracic society; Infectious diseases society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med*. 2005;171(4):388–416.
7. Ampel NM. Coccidioidomycosis in Persons Infected with HIV Type 1. *Clin Infect Dis*. 2005;41(8):1174–78.
8. Ananda-Rajah MR, Charles PG, Melvani S, et al. Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. *Scand J Infect Dis*. 2008;40(4):293–300.
9. Antonelli M, Azoulay E, Bonten M, et al. Year in review in Intensive Care Medicine 2009: I. Pneumonia and infections, sepsis, outcome, acute renal failure and acid base, nutrition and glycaemic control. *Intensive Care Med*. 2010;36(2):196–209.
10. Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: community-acquired pneumonia organization international cohort study results. *Arch Intern Med*. 2009;169(16):1515–24.
11. Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. *Am J Respir Crit Care Med* 2007;175(10): 1086–93.
12. Aviram G, Fishman JE, Boisselle PM. Thoracic Infections in Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome. *Semin Roentgenol*. 2007;42(1):23–36.



13. Bauer TT, Ewig S, Marre R, et al. CRB-65 predicts death from community-acquired pneumonia. *J Intern Med.* 2006;260(1):93–101.
14. Baughman RP. Protected-specimen brush technique in the diagnosis of ventilator-associated pneumonia. *Chest.* 2000;117(4/Suppl 2):203S–206S.
15. Blot S, Kouleli D, Dimopoulos G et al. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients. *Crit Care Med.* 2014;42(3):601–9.
16. Bouadma L, Wolff M, Lucet JC. Ventilator-associated pneumonia and its prevention. *Curr Opin Infect Dis.* 2012;25(4):395–404.
17. Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. *Intensive Care Med.* 2006;32(3):469–72.
18. Brar NK, Niederman MS. Management of community-acquired pneumonia: a review and update. *Ther Adv Respir Dis.* 2011;5(1):61–78.
19. Briel M, Meade M, Mercat A, et al. Higher vs. lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. *J Am Med Assoc.* 2010;303(9):865–73.
20. Bylund J, Campsall PA, Ma RC, et al. *Burkholderia cenocepacia* induces neutrophil necrosis in chronic granulomatous disease. *J Immunol.* 2005;174(6):3562–9.
21. Caballero J, Rello J. Combination of antibiotic therapy in community-acquired pneumonia. *Ann Intensive Care.* 2011;1:48. doi: 10.1186/2110-5820-1-48.
22. Caliendo AM, Gilbert DN, Ginocchio CC et al. Better tests, better care: improved diagnostics for infectious diseases. *Clin Infect Dis.* 2013;57(Suppl 3):S139–70.
23. Campbell GD Jr. Blinded invasive diagnostic procedures in ventilator-associated pneumonia. *Chest.* 2000;117(4/Suppl 2):207S–222S.
24. Canadian critical care trials group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. *N Engl J Med.* 2006;355(25):2619–30.
25. Carratalà J, Garcia-Vidal C. An update on *Legionella*. *Curr Opin Infect Dis.* 2010;23(2):152–7.
26. Carillo A, Gonzales-Diaz G, Ferrer M, et al. Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. *Intensive Care Med.* 2012;38(3):458–66.
27. Carron M, Freo U, Zorzi M, et al. Predictors of failure of noninvasive ventilation in patients with severe community-acquired pneumonia. *J Crit Care.* 2010;25(3):514–40.
28. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory and vasopressor support in community-acquired pneumonia. *Clin Infect Dis.* 2008;47(3):375–84.
29. Chastre J, Combes A, Luyt CE. The Invasive (Quantitative) Diagnosis of Ventilator-Associated Pneumonia. *Respir Care.* 2005;50(6):797–807.



30. Chastre J, Fagon JY. Ventilator-associated pneumonia. *Am J Respir Crit Care.* 2002;165(7):867–903.
31. Cheepsattayakorn A, Cheepsattayakorn R. Parasitic Pneumonia and Lung Involvement. *Biomed Res Int.* 2014;2014:874021. doi:10.1155/2014/874021.
32. Cho MC, Kim H, An D, et al. Comparison of sputum and nasopharyngeal swab specimen for molecular diagnosis of *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* and *Legionella pneumophila*. *Ann Lab Med.* 2012;32(2):133–8.
33. Cillóniz C, Ewig S, Ferrer M, et al. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. *Critical Care.* 2011;15(5):R209. doi: 10.1186/cc10444.
34. Cilloniz C, Ewig S, Polverino E, et al. Community-acquired pneumonia in outpatients: etiology and outcomes. *Eur Respir J.* 2010;40(4):931–8.
35. Coelho L, Salluh J, Soares M, et al. Patterns of C-reactive protein ratio response in severe community-acquired pneumonia: a cohort study. *Crit Care.* 2012;16(2):R53. doi: 10.1186/cc11291.
36. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. *Ann Intern Med.* 1998;129(6):433–40.
37. Corrales-Medina VF, Musher DM, Shachkina S, et al. Acute pneumonia and the cardiovascular system. *Lancet* 2013;381(9865):496–505.
38. Craven DE, Chroneou A. Nosocomial pneumonia. In Madell GL, Benett JE, Dolin R, editors. *Principles and Practices of Infectious Diseases.* 7th ed. Philadelphia: Elsevier Churchill Livingstone; 2009, p. 3717–24.
39. Craven DE, Palladino R, McQuillen DP. Healthcare-associated pneumonia in adults: management principles to improve outcomes. *Infect Dis Clin North Am.* 2004;18(4):939–62.
40. Cruciani M, Marcati P, Malena M, et al. Meta-analysis of diagnostic procedures for *Pneumocystis carinii* pneumonia in HIV-1-infected patients. *Eur Respir J.* 2002;20(4):982–9.
41. Dalhoff K, Ewig S; on behalf of the Guideline Development Group: Clinical Practice Guideline: Adult patients with nosocomial pneumonia – epidemiology, diagnosis and treatment. *Dtsch Arztebl Int.* 2013;110(38):634–40.
42. Dellinger RP. A Lifetime of Critical Care: Changes. *Crit Care Med.* 2016;44(4):653–4.
43. De Pascale G, Bello G, Tumbarello M, et al. Severe Pneumonia in Intensive Care. Cause, Diagnosis, Treatment and Management: A Review of the literature. *Curr Opin Pulm Med.* 2012;18(3):213–21.
44. Di Pasquale M, Aliberti S, Mantero M, et al. Non-Intensive Care Unit Acquired Pneumonia: A New Clinical Entity? *Int J Mol Sci.* 2016;17(3):287.
45. Di Pasquale M, Ferrer M, Esperatti M, et al. Assessment of severity of ICU-acquired pneumonia and association with etiology. *Crit Care Med.* 2014;42(2):303–12.



46. Ego A, Preiser JC, Vincent JL. Impact of diagnostic criteria on the incidence of ventilator-associated pneumonia. *Chest*. 2015;147(2):347–55.
47. Esan A, Hess DR, Raof S, et al. Severe hypoxemic respiratory failure: part 1 – ventilatory strategies. *Chest*. 2010;137(5):1203–16.
48. Espana PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. *Am J Respir Crit Care Med*. 2006;174(11):1249–56.
49. Ewig S, Welte T, Chastre J et al. Rethinking the concepts of community-acquired and health-care-associated pneumonia. *Lancet Infect Dis*. 2010;10(4):279–87.
50. Ewig S, Woodhead M, Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. *Intensive Care Med*. 2011;37(2):214–23.
51. Fabregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. *Thorax*. 1999;54(10):867–73.
52. Ferrer M, Cosentini R, Nava S. The use of non-invasive ventilation during acute respiratory failure due to pneumonia. *Eur J Inter Med*. 2012;23(5):420–8.
53. Ferrer M, Difrancesco LF, Liapikou A et al. Polymicrobial Intensive Care Unit-acquired Pneumonia: Prevalence, Microbiology and Outcome. *Crit Care*. 2015;19:450.
54. Ferrer M, Esquinas A, Leon M, et al. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. *Am J Respir Crit Care Med*. 2003;168(12):1438–44.
55. File TM Jr. New diagnostic tests for pneumonia : what is their role in clinical practice? *Clin Chest Med*. 2011;32(3):417–30.
56. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. *JAMA*. 1996;275(2):134–41.
57. Fishman JA. Prevention of infection due to *Pneumocystis carinii*. *Anti-microb Agents Chemother*. 1998;42(5):995–1004.
58. Flanders SA, Stein J, Shochat G, et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. *Am J Med*. 2004;116(8):529–35.
59. Frat JP, Arnaud W, Thille AW, et al. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. *N Engl J Med*. 2015;372(23):2185–96.
60. Gabrhelík T, Hanulík V, Jakubec P, et al. Porovnání validity různých vzorků biologického materiálu z dýchacích cest a jejich přínosu v detekci původců nozokomiální pneumonie. *Klin Mikrobiol Infekc Lek*. 2015;21(1):4–9.
61. Gamache J, Harrington A, Kamangar N, et al. Bacterial pneumonia. *Medscape*. [updated 2016 Dec 07; cited 2017 Mar 25]. Available from: <http://emedicine.medscape.com/article/300157-overview>.
62. Garin N, Marti C. Community-acquired pneumonia: the elusive quest for the best treatment strategy. *J Thorac Dis*. 2016;8(7):E571–E574.



63. Gattarello S, Lagunes L, Vidaur L, et al. Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study. *Crit Care*. 2015;19:335.
64. Gattinoni L, Carlesso E, Taccone P, et al. Prone positioning improves survival in severe ARDS: a pathophysiologic review and individual patient metaanalysis. *Minerva Anestesiol*. 2010;76(6):448–54.
65. Giantsou E, Liratzopoulos N, Efraimidou E, et al. Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. *Intensive Care Med*. 2005;31(11):1488–94.
66. Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. *Clin Infect Dis*. 2011;52(4):346–50.
67. Gilbert DN, Spellberg B, Bartlett JG. Recommendations for diagnostic studies in respiratory tract infections. *Clin Infect Dis*. 2010;51(1):150–70.
68. Gottlieb M, Bailitz J. Do Corticosteroids Provide Benefit to Patients With Community-acquired Pneumonia? *Ann Emerg Med*. 2016;67(5):640–2.
69. Gudlaugsson O. Attributable mortality of nosocomial candidemia, revisited. *Clin Infect Dis*. 2003;37(9):1172–7.
70. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. *Am J Respir Crit Care Med*. 2005;171(4):388–416.
71. Hanulík V, Uvízl R, Husičková V, et al. Bakteriální původci pneumonií u pacientů v intenzivní péči. *Klin Mikrobiol Infekc Lek*. 2011;17(4):135–40.
72. Herkel T, Uvízl R, Adamus M, et al. Epidemiology of hospital-acquired pneumonia: results of a Central European multicenter, prospective, observational study compared with data from the European region. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2016;160(3):448–55.
73. Holm A, Nexoe J, Bistrup LA, et al. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. *Br J Gen Pract* 2007;57(540):547–54.
74. Huang L, Morris A, Limper AH et al. An Official ATS Workshop Summary: Recent Advances and Future Directions in Pneumocystis Pneumonia (PCP). *The Proceedings of the American Thoracic Society*. 2006;3(8):655–64.
75. Imtiaz T, Thomson F, Innes A, et al. *Candida krusei* bronchopneumonia with nodular infiltrates in a patient with chronic renal failure on haemodialysis – case report and review of literature. *Mycoses*. 2011;54(5):e611–4.
76. Jakubec P, Kolek V, Kolář M. Diagnostika a léčba těžké pneumonie. In: Kolek V, et al. *Doporučené postupy v pneumologii*. 2nd ed. Praha: Maxdorf; 2013. p. 145–60.
77. Japanese Respiratory Society. Diagnosis of hospital-acquired pneumonia and methods of testing for pathogens. *Respirology*. 2009;14(Suppl 2):S10–S22.
78. Jeanes AC, Owens CM. Chest imaging in the immunocompromised child. *Paediatr Respir Rev*. 2002;3(1):59–69.



79. Jesenak M, Banovcin P, Jesenakova B, et al. Pulmonary Manifestations of Primary Immunodeficiency Disorders in Children. *Frontiers in Pediatrics*. 2014;2:77.
80. Johansson N, Kalin M, Hedlund J. Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. *Scand J Infect Dis*. 2011;43(8):609–15.
81. Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. *Clin Infect Dis* 2010;50(2):202–9.
82. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated pneumonia. *Clin Infect Dis*. 2010;51(Suppl 1):S81–S87.
83. Kalanuria AA, Zai W, Mirski M. Ventilator-associated pneumonia in the ICU. *Crit Care*. 2014;18(2):208.
84. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Disease Society of America and the American Thoracic Society. *Clin Infect Dis*. 2016;63(5):e61–111.
85. Karhu J, Ala-Kokko TI, Ohtonen P, et al. Severe community-acquired pneumonia treated with beta-lactam-respiratory quinolone vs. beta-lactam-macrolide combination. *Acta Anaesthesiol. Scand*. 2013;57(5):587–93.
86. Karhu J, Ala-Kokko TI, Ylipalosaari P, et al. Hospital and long-term outcomes of ICU-treated severe community- and hospital-acquired, and ventilator-associated pneumonia patients. *Acta Anaesthesiol Scand*. 2011;55(10):1254–60.
87. Kawai S, Ochi M, Nakagawa T, et al. Antimicrobial therapy in community-acquired pneumonia among emergency patients in a university hospital in Japan. *J Infect Chemother*. 2004;10(6):352–8.
88. Kollef MH, Snorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. *Chest*. 2005;128(6): 3854–62.
89. Koleff MH, Morrow LE, Niederman MS, et al. Clinical Characteristics and Treatment Patterns Among Patients With Ventilator-Associated Pneumonia. *Chest*. 2006;129(5):1210–8.
90. Kolář M. Komunitní pneumonie z pohledu mikrobiologa. *Stud Pneumol Phtiseol* 2003;63(5):164–7.
91. Kolář M, Urbánek K, Čekanová L. Podklady pro racionální antibiotickou léčbu komunitních bakteriálních infekcí. *Klin Farmakol Farmac*. 2003;17:22–4.
92. Kolek V. Pneumonie – diagnostika a léčba. Praha: Triton; 2003.
93. Kolek V. Prognóza nemocných s komunitní pneumonií. Poučení z klinických doporučení, skórovacích systémů a dalších parametrů. *Postgraduální medicína*. 2013;15(příloha č.3):832–5.
94. Kolek V. Komunitní pneumonie dospělých – doporučené postupy pro praktické lékaře. Praha: Česká lékařská společnost Jana Evangelisty Purkyně; 2002.



95. Kolek V. Diagnostika a léčba komunitně získané pneumonie dospělých. In: Bourek A, Seifert B, Suchý M, editors. Programy kvality a standardy léčebných postupů. Praha: Verlag Dashöfer; 2001: RESP/2,1–12.
96. Kolek V. Pneumonie v České republice. Bulletin ČPFS 2001;11:27–9.
97. Kolek V. Diagnostika a léčba komunitně získané pneumonie dospělých. Standard léčebného plánu. In: Forýtková L, Bourek A. Programy kvality a standardy léčebných postupů. RESP. 2006;2:1–16.
98. Kolek V. Jaké jsou názory na diagnostiku a léčbu komunitní pneumonie v současných klinických doporučeních? Stud Pneumol Phthiseol. 2003;63(1):20–6.
99. Kolek V. Standard diagnostiky a léčby komunitně získané pneumonie dospělých. Bulletin ČPFS. 1995;5:9–12.
100. Kolek V, Fila L, Fojtů H, et al. Pneumonie vyžadující hospitalizaci: výsledky dvouleté multicentrické studie v České republice. Int Med Prax. 2002;7:347–52.
101. Kolek V, Kolář M, Kašák V, et al. Diagnostika a léčba komunitní pneumonie dospělých. In: Kolek V, et al. Doporučené postupy v pneumologii. 2nd ed. Praha: Maxdorf; 2013. p. 127–45.
102. Kolek V, Kolář M, Kašák V, et al. Diagnostika a léčba komunitní pneumonie dospělých. In: Kolek V, Kolář M, Kašák V, et al. Klinické doporučení, diagnostika a léčba komunitní pneumonie dospělých. Praha: Dashofer; 2006.
103. Kolek V, Kašák V. Pneumologie: Vybrané kapitoly pro praxi. Praha: Maxdorf; 2010.
104. Kontoyannis DP, Reddy BT, Torres HA, et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis. 2002;34(3):400–3.
105. Kothe H, Bauer T, Marrer R, et al. Outcome of community-acquired pneumonia: influence of age, residence status, and antimicrobial treatment. Eur Respir J. 2008;32(1):139–46.
106. Kowalczyk W, Rybicki Z, Tomaszewski D, et al. The comparison of different bronchial aspirate culturing methods in patients with ventilator-associated pneumonia. Anestezjol Intens Ter. 2011;43(2):64–8.
107. Krcmery V, Barbnes AJ. Non-albicans *Candida* spp. causing fungaemia: pathogenicity, and antifungal resistance. J Hosp Infect. 2002;50(4):243–60.
108. Kruger S, Ewig S, Marre R. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008;31(2):349–55.
109. Leal FE, Cavazzana CL, de Andrade HF et al. *Toxoplasma gondii* Pneumonia in Immunocompetent Subjects: Case Report and Review. Clin Infect Dis. 2007;44(6):62–6.
110. Lee JS, Giesler DL, Gellad WF, et al. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review. JAMA. 2016;315(6):593–602.
111. Liapikou A, Ferrer M, Polverino E, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/



- American Thoracic Society guidelines to predict an intensive care unit admission. *Clin Infect Dis*. 2009;48(4):377–85.
112. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax*. 2009;64(III):iii1–iii55.
  113. Lindenauer PK, Lagu T, Shieh MS, et al. Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003–2009. *JAMA*. 2012;307(13):1405–13.
  114. Luks AM, Neff MJ. Pneumocystis jiroveci Pneumonia. *Respiratory Care*. 2007;52(1):59–63.
  115. Lung M, Codina G. Molecular diagnosis in HAP/VAP. *Curr Opin Crit Care*. 2012;18(5):487–94.
  116. Macfarlane JT, Boswell T, Douglas G, et al. BTS guidelines for the management of community acquired pneumonia in adults. *Thorax*. 2001;56(Suppl 4):IV1–64.
  117. Magill SS, Edwards JR, Fridkin SK. Emerging Infections Programme Healthcare-Associated Infections Antimicrobial Use Prevalence Survey Team. Survey of healthcare-associated infections. *N Engl J Med*. 2014;370:2542–3.
  118. Mandell LA, Wunderink RG, Anzueto A, et al. IDSA/ATS Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. *Clin Infect Dis*. 2007;44(Suppl 2):S27–72.
  119. Mansharamani NG, Garland R, Delaney D, et al. Management and outcome patterns for adult *Pneumocystis carinii* pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. *Chest*. 2000;118(3):704–11.
  120. Marti C, Garin N, Groscurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. *Critical Care*. 2012;16(4):R141.
  121. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. *Intensive Care Med*. 2010;36(4):612–620.
  122. Martin SI, Fishman JA. *Pneumocystis Pneumonia* in Solid Organ Transplantation. *Am J Transplant*. 2013;13(Suppl 4):272–9.
  123. Masur H, Rosen PP, Armstrong D. Pulmonary disease caused by *Candida* species. *Am J Med*. 1977;63(6):914–25.
  124. McCabe C, Kirchner C, Zhang H, et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. *Arch Intern Med*. 2009;169(16):1525–31.
  125. Meduri GU, Beals DH, Maijub AG et al. Protected bronchoalveolar lavage. A new bronchoscopic technique to retrieve uncontaminated distal airway secretion. *Am Rev Respir Dis*. 1991;143(4 Pt 1):855–64.
  126. Meduri GU, Chastre J. The Standardization of Bronchoscopic Techniques for Ventilator-Associated Pneumonia. *Chest*. 1992;102(5):557S–564S.



127. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomized prevention studies. *Lancet Infect Dis.* 2013;13(8):665–71.
128. Metersky ML, Waterer G, Nsa W, et al. Predictors of in-hospital vs post-discharge mortality in pneumonia. *Chest* 2012;142(2):476–81.
129. Miquez-Burbano MJ, Flores M, Ashkin D, et al. Non-tuberculous mycobacteria disease as a cause of hospitalization in HIV-infected subjects. *Int J Infect Dis.* 2006;10(1):47–55.
130. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. *Infect Control Hosp Epidemiol.* 2005;26(6):540–7.
131. Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. *Chest.* 2010;138(1):121–9.
132. Munoz P, Sánchez-Somolinos M, Alcalá L, et al. *Candida krusei* fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. *J Antimicrob Chemother.* 2005;55(2):188–93.
133. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. *Lancet Respir Med.* 2014;2(5):395–404.
134. Nair GB, Niederman MS. Ventilator-associated pneumonia: present understanding and ongoing debate. *Intensive Care Med.* 2015;41(1):34–48.
135. Nair GB, Niederman MS. Community-acquired pneumonia: an unfinished battle. *Med Clin North Am.* 2011;95(6):1143–61.
136. National Institute for Health and Care Excellence, NICE. Baden-Daintre (editor). NICE Pneumonia in adults: diagnosis and management. NICE 2014 [cited 2017 Mar 20]. Available from: <http://www.nice.org.uk/guidance/cg191>.
137. Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). *J Am Med Assoc.* 2011;306(15):1659–68.
138. Notarangelo LD, Plebani A, Mazzolari E, et al. Genetic causes of bronchiectasis: primary immune deficiencies and the lung. *Respiration.* 2007;74(3):264–75.
139. Ostrofsky-Zeichner L, Rex RH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream *Candida* isolates in the United States. *Antimicrob Agents Chemother.* 2003;47(10):3149–54.
140. Papazian L, Thomas P, Garbe L, et al. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. *Am J Respir Crit Care Med.* 1995;152(6):1982–91.
141. Patroniti N, Zangrillo A, Pappalardo F, et al. The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: prepa-



- ration for severe respiratory emergency outbreaks. *Intensive Care Med.* 2011;37(9):1447–57.
142. Petersen E, Edvinsson B, Lundgren B, et al. Diagnosis of pulmonary infection with *Toxoplasma gondii* in immunocompromised HIV-positive patients by real-time PCR. *Eur J Clin Microbiol Infect Dis.* 2006;25(6):401–4.
  143. Petrocheilou-Paschou V, Georgilis K, Kontoyannis DP, et al. Pneumonia due to *Candida krusei*. *Clin Microbiol Infect.* 2002;8(12):806–9.
  144. Peyrani P, Ramirez J. What is the association of cardiovascular events with clinical failure in patients with community-acquired pneumonia? *Infect Dis Clin North Am* 2013;27(1):205–10.
  145. Poljak V, Krč I, Ehrman J. Systémové mykózy. In: *Manuál infekčních nemocí*. Konice: Solen; 2000. p. 175.
  146. Ramirez P, Ferrer M, Martí V, et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. *Crit Care Med.* 2011;39(10):2211–17.
  147. Ranasuriya G, Mian A, Boujaoude Z. Pulmonary toxocarasis: a case report and literature review. *Infection.* 2014;42(3):575–8.
  148. Rea-Neto A, Youssef NCM, Tuche F, et al. Diagnosis of ventilator-associated pneumonia: a systematic review of the literature. *Crit Care* 2008;12(2):R56.
  149. Rello J. Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. *Crit Care* 2008;12(6 Suppl):S2.
  150. Rello J, Lisboa T, Koulenti D. Respiratory infections in patients undergoing mechanical ventilation. *Lancet Respir Med.* 2014;2(9):764–74.
  151. Rello J, Rodriguez A, Lisboa T, et al. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. *Crit Care Med* 2009;37(2):456–62.
  152. Rello J, Vidaur L, Sandiumenge A et al. De-escalation therapy in ventilator-associated pneumonia. *Crit Care Med.* 2004;32(11):2183–90.
  153. Renaud B, Santin A, Coma E, et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. *Crit Care Med.* 2009;37(11):2867–74.
  154. Restrepo MI, Anzueto A. Severe community-acquired pneumonia. *Infect Dis Clin North Am.* 2009;23(3):503–20.
  155. Restrepo MI, Mortensen EM, Rello J, et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. *Chest* 2010;137(3):552–7.
  156. Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. *Eur Respir J.* 2009;33(1):153–9.
  157. Restrepo M, Peterson J, Fernandez JF, et al. Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. *Respir Care.* 2013;58(7):1220–5.



158. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Med.* 2017;43(3):304–77.
159. Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis. *Clin Microbiol Rev.* 2012;25(2):264–96.
160. Sarwar G, de Malmanche T, Rassam L, et al. Chronic granulomatous disease presenting as refractory pneumonia in late adulthood. *Respirol Case Rep.* 2015;3(2):54–6.
161. Schuetz P, Muller B, Christ-Crain M et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev.* 2012;(9):CD007498.
162. Schulgen G, Kropec A, Kappstein I, et al. Estimation of extra hospital stay attributable to nosocomial infections: heterogeneity and timing of events. *J Clin Epidemiol.* 2000;53(4):409–17.
163. Shah BA, Singh G, Naik MA et al. Bacteriological and clinical profile of Community acquired pneumonia in hospitalized patients. *Lung India.* 2010;27(2):54–7.
164. Shibli F, Chazan B, Nitzan O, et al. Etiology of community-acquired pneumonia in hospitalized patients in northern Israel. *Isr Med Assoc J* 2010;12(8):477–82.
165. Shimada T, Noguchi Y, Jackson JL, et al. Systematic review and meta-analysis: urinary antigen tests for legionellosis. *Chest.* 2009;136(6):1576–85.
166. Shorr AF, Sherner JH, Jackson WL, et al. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. *Crit Care Med.* 2005;33(1):46–53.
167. Singh S, Gopinath K, Shahdad S, et al. Nontuberculous Mycobacterial Infections in Indian AIDS Patients Detected by a Novel Set of ESAT-6 Polymerase Chain Reaction Primers. *Jpn J Infect Dis.* 2007;60(1):14–8.
168. Skříčková J. Pneumocystová pneumonie. *Klin Farmakol Farm.* 2005;19(2):106–10.
169. Skříčková J. Pneumocystová pneumonie – epidemiologie, diagnostika, léčba a profylaxe. *Stud Pneumol Phthiseol.* 2006;66(5):208–20.
170. Skříčková J. Komunitní pneumonie v intenzivní medicíně. *Postgraduální medicína.* 2010;9:1070–9.
171. Skříčková J. Nozokomiální pneumonie. *Vnitř Lék* 2017;63(7–8):518–26.
172. Sligl WI, Eurich DT, Marrie TJ. Only severely limited, pre-morbid functional status is associated with short- and long-term mortality in patients with pneumonia who are critically ill: a prospective observational study. *Chest.* 2011;139(1):88–94.
173. Smith MB, Boyars MC, Veasey S, et al. Generalized Tuberculosis in the Acquired Immune Deficiency Syndrome. *Arch Patol Labor Med.* 2000;124(9):1267–74.
174. Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. *J Clin Microbiol* 2003;41(7):2810–3.



175. Snyderman DR, Limaye AP, Potena L, et al. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. *Transplant Proc.* 2011;43(3 Suppl):S1–S17.
176. Sopena M, Heras E, Casas I, et al. Risk factors for hospital-acquired pneumonia outside the intensive care unit: A case-control study. *Am J Infect Control.* 2014;42(1):38–42.
177. Sopena M, Sabria M, Neunos Study Group. Multicenter study of hospital-acquired pneumonia in non-ICU patients. *Chest.* 2005;127(1):213–9.
178. Sordé R, Falcó V, Lowak M, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. *Arch Intern Med.* 2011;171(2):166–72.
179. Stolz D, Smyrniotis N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomized study. *Eur Respir J.* 2009;34(6):1364–75.
180. Sud S, Friedrich JO, Taccone P, et al. Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. *Intensive Care Med.* 2010;36(4):585–99.
181. Ševčík P, Skříčková J, Šrámek V, et al. *Záněty plic v intenzivní medicíně.* Praha: Galén; 2004.
182. Thomas CF Jr., Limper AH. Pneumocystis pneumonia. *N Eng J Med.* 2004;350(24):2487–98.
183. Torres A, El-Ebiary M. Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia. *Chest.* 2000;117(4/Suppl 2):198S–202S.
184. Torres A, El-Ebiary M, Padro L, et al. Validation of different techniques for the diagnosis of ventilator-associated pneumonia. Comparison with immediate postmortem pulmonary biopsy. *Am J Respir Crit Care Med.* 1994;149(2 Pt 1):324–31.
185. Torres A, Ewig S, editors. *Nosocomial and Ventilator-Associated Pneumonia.* 1st ed. Plymouth: European Respiratory Society; 2011.
186. Torres A, Ewig S, Lode H, et al. European HAP working group. Defining, treating and preventing hospital acquired pneumonia. *Intensive Care Med.* 2009;35(1):9–29.
187. Torres-Tortosa M, Arrizabalaga J, Villanueva JL, et al. Prognosis and Clinical Evaluation of Infection Cause by *Rhodococcus equi* in HIV-infected Patients: A Multicenter Study of 67 Cases. *Chest.* 2003;123(6):1970–6.
188. Uvizl R, Hanulík V, Husická V, et al. Hospital-acquired pneumonia in ICU patients. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2011;155(4):373–8.
189. Vašáková M. *Moderní farmakoterapie v pneumologii.* Praha: Maxdorf; 2016.
190. Vašáková M, et al. *Bronchologie a pneumologická cytodiagnostika.* Praha: Maxdorf; 2017.



191. Velásquez JN, Ledesma BA, Nigro mg. Pulmonary toxoplasmosis in human immunodeficiency virus-infected patients in the era of aniretroviral therapy. *Lung India*. 2016;33(1):88–91.
192. Viasus D, Garcia-Vidal C, Manresa F, et al. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. *J Infect* 2013;66(1):27–31.
193. Vincent JL, Bassetti M, François B, et al. Advances in antibiotic therapy in the critically ill. *Crit Care*. 2016;20(1):133.
194. Voirit G, Dury S, Parrot A, et al. Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. *Chest*. 2011;139(2):387–94.
195. Wan YD, Sun TW, Liu ZQ, et al. Efficacy and Safety of Corticosteroids for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. *Chest*. 2016;149(1):209–19.
196. Wang Y, Eldridge N, Metersky ML, et al. National trends in patient safety for four common conditions, 2005–2011. *N Engl J Med*. 2014;370(4):341–51.
197. Weber DJ, Rutala WA, Sickbert-Bennett EE, et al. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. *Infect Control Hosp Epidemiol*. 2007;28(7):825–31.
198. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. *Lancet*. 2007;369(9572):1553–64.
199. Wolff AJ, O' Donnell AE. HIV-related pulmonary infections: a review of the recent literature. *Curr Opin Pulm Med*. 2003;9(3):210–4.
200. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections- Summary. *Clin Microbiol Infect*. 2011;17(6):1–24.
201. Wunderink RG. Adjunctive therapy in community-acquired pneumonia. *Semin Respir Crit Care Med*. 2009;30(2):146–53.
202. Yandiola PP, Capelastegui A, Quintana J, et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. *Chest*. 2009;135(6):1572–9.
203. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. *Clin Infect Dis*. 2005;41(9):1232–9.
204. Žáčková P. Plicní mykózy. In: Vašáková M. *Moderní farmakoterapie v pneumologii*. Praha: Maxdorf, 2016.
205. Žáčková P, Vašáková M. Komunitní pneumonie. *Prakt Lék*. 2008; 88(10):603–9.